Logo

American Heart Association

  14
  0


Final ID: Mo4066

Electrocardiographic Aging in Genetic Cardiomyopathies: Insights from an Artificial Intelligence-Enabled Electrocardiogram Analysis

Abstract Body (Do not enter title and authors here): Background: Arrhythmogenic and dilated cardiomyopathies (ACM/DCM) are associated with adverse cardiovascular outcomes, including sudden death. Artificial intelligence (AI)-enabled electrocardiographic aging algorithms estimate biological age from 12-lead tracings and predict cardiovascular outcomes in the general population. However, their utility in genetic ACM/DCM has not been studied.

Methods: Retrospective review of 1,045 genotype-positive ACM/DCM patients was used to identify those with a pathogenic/likely pathogenic variant in ClinGen-classified definitive/strong evidence ACM/DCM-susceptibility genes. Following exclusion of patients without a baseline ECG for analysis (e.g. paced rhythms), the AI-ECG age gap (AI-EAG) was calculated by subtracting chronological from AI-ECG age. Genes were grouped into functional categories: desmosomal (PKP2, DSP, DSG2, DSC2, JUP), nuclear envelope (LMNA), sarcomeric (TTN, MYH7, TNNT2), cytoskeleton/Z-disc (FLNC, DES, DMD, BAG3), and regulatory/ion channel (PLN, RBM20, SCN5A). Cardiac MRI data included left ventricular structure, function, and late gadolinium enhancement (LGE) presence and pattern. Mann-Whitney U was used for group comparisons; results are shown as median (IQR).

Results: Overall, 824 patients (52.8% male; median age of 40.7 years, IQR 26.5–53.4; and median AI-EAG of 7.49 years, IQR 0.43–15.26) were included. DES variant-positive patients had the highest (19.98 years, IQR 9.66–23.21) and BAG3 variant-positive patients the lowest (–0.95 years, IQR -6.05–7.61) AI-EAGs. Among gene groups, nuclear envelope had the highest (15.12 years, IQR 6.79–25.17) and sarcomeric the lowest (5.75 years, IQR -0.69-14.01) AI-EAGs. Cardiac MRI was available for 538/824 (65%) of which 233/538 (43.3%) had LGE. No significant difference in AI-EAG was observed between LGE-positive and -negative patients (6.99 vs. 7.94 years; p=0.831). However, several LGE patterns were associated with significantly higher AI-EAGs: subepicardial (9.88 vs. 6.84; p=0.004), transmural (13.83 vs. 7.25; p=0.012), apical (12.89 vs. 7.17; p=0.002), and septal (8.91 vs. 7.19; p=0.016).

Conclusion: AI-EAG varies by gene and functional group, possibly reflecting gene-specific myocardial remodeling. While certain LGE patterns were linked to increased biological aging, overall LGE status was not. These findings suggest AI-EAG may capture disease activity that is distinct from LGE and could serve as a complementary, non-invasive biomarker in genetic ACM/DCM.
  • Sularz, Agata  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Ackerman, Michael  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Giudicessi, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Castrichini, Matteo  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Garmany, Ramin  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Bos, Johan  ( Mayo Clinic College of Medicine , Rochester , Minnesota , United States )
  • Attia, Zachi  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Noseworthy, Peter  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Friedman, Paul  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Lopez-jimenez, Francisco  ( MAYO CLINIC COLL MEDICINE , Rochester , Minnesota , United States )
  • Milone, Margherita  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Author Disclosures:
    Agata Sularz: DO NOT have relevant financial relationships | Michael Ackerman: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:UpToDate:Active (exists now) ; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Solid Biosciences:Active (exists now) ; Royalties/Patent Beneficiary:Prolaio:Active (exists now) ; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now) ; Royalties/Patent Beneficiary:AliveCor:Active (exists now) ; Consultant:Tenaya Therapeutics:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Invitae:Past (completed) ; Consultant:Illumina:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:BioMarin Pharmaceutical:Past (completed) | John Giudicessi: DO have relevant financial relationships ; Consultant:Avidity Biosciences:Active (exists now) ; Consultant:Nuevocor Therapeutics:Active (exists now) ; Consultant:Citizen Health:Active (exists now) | Matteo Castrichini: DO NOT have relevant financial relationships | Ramin Garmany: DO NOT have relevant financial relationships | Johan Bos: DO NOT have relevant financial relationships | Zachi Attia: No Answer | Peter Noseworthy: DO have relevant financial relationships ; Royalties/Patent Beneficiary:Anumana:Active (exists now) | Paul Friedman: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Anumana:Active (exists now) ; Other (please indicate in the box next to the company name):Eko Health:Active (exists now) ; Other (please indicate in the box next to the company name):AliveCor:Active (exists now) | Francisco Lopez-Jimenez: DO have relevant financial relationships ; Advisor:Novo Nordisk:Active (exists now) ; Other (please indicate in the box next to the company name):Up-To-Date Author of chapter:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:WizeHealth:Past (completed) ; Royalties/Patent Beneficiary:Anumana:Active (exists now) ; Consultant:New Amsterdam Pharma:Past (completed) ; Consultant:MediWhale:Past (completed) ; Researcher:Select Research:Past (completed) ; Consultant:K-Health:Active (exists now) ; Consultant:Kento Health:Active (exists now) ; Advisor:Anumana:Active (exists now) | Margherita Milone: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Early Detection of Cardiovascular Disease 2

Monday, 11/10/2025 , 01:00PM - 02:00PM

Abstract Poster Board Session

More abstracts on this topic:
Activin Type IIA Receptor Inhibition Decreases Atrial Fibrillation Inducibility In Mice Via a Smurf1-Connexin43 Mechanism

Castro Claire, Lee Se-jin, Ellinor Patrick, Rosenzweig Anthony, Roh Jason, Bapat Aneesh, Hobson Ryan, Yu Andy, Li Haobo, Xiao Chunyang, Xia Peng, Yeri Ashish, Yu Paul

A human cardiomyocyte model of CD36 haploinsufficiency uncovers fatty acid oxidation deficits driving dilated cardiomyopathy

Al Sayed Zeina, Klattenhoff Carla, Aragam Krishna, Ellinor Patrick, Willcox Jon, Zheng Alice, Koledova Vera, Srivastava Salil, Yin Xiaofei, Chaffin Mark, Rigaud Vagner, Kovacs-bogdan Erika

More abstracts from these authors:
The Artificial Intelligence-Derived Electrocardiographic Age Gap is Associated with Adverse Clinical Outcomes in Cardiac Laminopathy

Castrichini Matteo, Ackerman Michael, Milone Margherita, Giudicessi John, Sularz Agata, Garmany Ramin, Tester David, Bos Johan, Attia Zachi, Noseworthy Peter, Friedman Paul, Lopez-jimenez Francisco

Prevalence, Clinical Characteristics, and Outcomes of Patients with Genotype-Positive Arrhythmogenic Cardiomyopathy Presenting with a Sentinel Sudden Cardiac Arrest

Swain William, Garmany Ramin, Castrichini Matteo, Bos Johan, Neves Raquel, Ackerman Michael, Giudicessi John

You have to be authorized to contact abstract author. Please, Login
Not Available